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Abstract: Glucocorticoids are commonly used in various fields within medicine. One of their 
most common and clinically significant side effects is glucocorticoid-induced osteoporosis 
(GIOP). GIOP is a disease leading to progressive decreases in bone mineral density, decreased 
bone strength, and increased risk of skeletal fractures. GIOP has a significant impact on 
the morbidity and health-related quality of life of the patients it affects. Glucocorticoids 
have  deleterious  effects  on  bone  through  promoting  osteoblast  apoptosis  and  inhibiting 
osteoblastogenesis.  Teriparatide  exerts  anabolic  effects  on  bone,  so  it  is  understandable 
why teriparatide is thought to be a rational treatment option. Clinical studies have indicated 
teriparatide is efficacious in the treatment of GIOP to improve bone mineral density values at 
the lumbar spine and femoral neck. Some evidence also suggests teriparatide may reduce rates 
of vertebral fractures in GIOP patients. Overall, this review of the current clinical evidence 
suggests teriparatide may be an efficacious and promising agent in the treatment of GIOP.
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Introduction
Glucocorticoids are widely used in various specialties in medicine. It is estimated that 
2.5% of the elderly population (aged 70–79 years) are prescribed oral   glucocorticoid 
therapy.1 These agents play an important role in the treatment of a variety of dis-
eases, with significant impact on both morbidity and mortality in patients with these 
diseases. However, glucocorticoids are not benign therapies and are associated with 
a number of side effects. One of the most common and clinically significant side 
effects is glucocorticoid-induced osteoporosis (GIOP). GIOP is a disease   leading to 
  progressive decreases in bone mineral density, decreased bone strength, and increased 
risk of skeletal   fractures.2 It is estimated that 30%–50% of patients on long-term 
  glucocorticoid therapy will sustain a fracture.3 The risk of fracture is also related 
to the dosage of   glucocorticoids. The estimated rates of vertebral and hip fractures 
are estimated to be 20% for daily prednisone doses #5 mg, and up to 60% for daily 
doses $20 mg, for more than three months.4,5 Even at low doses (,2.5 mg per day), 
there is an increased risk of vertebral fractures. As the dose was increased from 2.5 mg 
to 7.5 mg, and .7.5 mg, the risk of vertebral fracture increased accordingly.1 Patients 
on higher doses of   glucocorticoids are also more likely to require these agents for a 
longer duration.4
Decreases in bone mineral density were evident by 3–6 months after initiating glu-
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after 6–12 months on glucocorticoid therapy.6 After the 
one-year mark, there is a drop in the rate of BMD decline. 
Fracture rates were similar between males and females. 
However, with advancing age, rates of fractures in females 
rose exponentially, although this was seen in both control 
and glucocorticoid groups.5
Inhaled glucocorticoids have also been evaluated 
  regarding their effect on bone metabolism. High doses of 
inhaled glucocorticoids have been associated with a decline 
in BMD.7,8 It is still unclear if inhaled glucocorticoids increase 
fracture rates. There have been reports of increased fractures 
in both adults and children on inhaled glucocorticoids, but 
a similar fracture rate was also seen in inhaled nonsteroidal 
bronchodilator groups as well.9,10
Pathophysiology of glucocorticoid 
effects on bone
Bone loss resulting from glucocorticoid use occurs through 
a number of mechanisms. As described earlier, there is an 
early and rapid phase of bone resorption during the first year 
of glucocorticoid use. This phase is characterized by a state 
of increased bone resorption.11
The mechanisms by which glucocorticoids promote bone 
resorption are not fully understood. Receptor   activation of 
nuclear factor-κB ligand (RANK-L) likely plays a key role, and 
the expression of RANK-L is significantly increased in osteo-
blasts and stromal cells when stimulated by glucocorticoids.11 
Macrophage colony-stimulating factor levels are also increased 
with exposure to glucocorticoids through increased nuclear 
transcription of the macrophage colony-stimulating factor 
gene.11 RANK-L and macrophage colony-stimulating factor 
both play pivotal roles in inducing osteoclastogenesis and 
decreasing osteoclast apoptosis, thereby leading to increased 
bone resorption (Figure 1). In addition, osteoprotegerin 
expression is also decreased in osteoblasts and stromal cells 
in the presence of glucocorticoids.12 Osteoprotegerin plays a 
counterregulatory role in the effects of RANK-L, and down-
regulation of osteoprotegerin also enhances osteoclastogenesis 
and decreases rates of osteoclast apoptosis.12
In addition, glucocorticoids also have important effects 
on osteoblasts. Long-term glucocorticoid use has effects 
on both osteoblast numbers and their function13 (Figure 1). 
Glucocorticoids lead to a subsequent decrease in osteoblas-
togenesis through downregulation of the Wnt signalling 
pathway. There is also an upregulation of   peroxisome 
proliferator-activated receptor-γ2 (PPAR-γ2) which leads 
to a decrease in osteoblastogenesis.14 PPAR-γ2 activation 
favors differentiation of bone marrow stromal cells into 
the adipocyte lineage rather than the osteoblast lineage, 
thus decreasing   osteoblastogenesis.14 Glucocorticoids also 
activate caspase 3, which is an effector molecule playing 
a role in several apoptotic pathways. The activation of 
  caspase 3 leads to increased apoptosis of both osteoblasts 
and osteocytes.15 Loss of osteocytes also has a major impact 
on bone microarchitecture as a result of disruption of the 
osteocyte-canalicular network, which subsequently impairs 
repair of damaged bone.16,17
Mechanism of parathyroid  
hormone action
Parathyroid hormone plays an essential role in the regulation 
of calcium metabolism. When parathyroid hormone levels 
are continuously elevated, as seen in patients with primary or 
secondary hyperparathyroidism, there is a deleterious effect 
on bone, leading to a high turnover state and subsequent 
loss of cortical bone. However, intermittent pulsatile 
administration of parathyroid hormone has a contrary effect, 
leading to anabolic effects on bone. This accounts for the 
anabolic effects of teriparatide, ie, recombinant human 
parathyroid hormone-(1–34), shown in Figure 2.
Osteoblasts and stromal cells in the bone marrow have 
surface receptors for parathyroid hormone. Intermittent 
pulses of parathyroid hormone activate different mechanisms 
to those activated by continuous administration of parathyroid 
hormone, and thus accounts for the different effects on bone 
metabolism.18
The intermittent pulses of parathyroid hormone bind to 
the parathyroid hormone-1 receptor, a G-protein-coupled 
protein, which leads to subsequent activation of cyclic AMP-
dependent protein kinase A and protein kinase C signalling 
pathways, both of which play key roles in regulating osteo-
blastogenesis and osteoblast function.19
Insulin-like growth factor I (IGF-1) is another regulator 
of osteoblast function. IGF-1 acts directly on bone tissue as 
both a growth hormone-dependent hormone and as a local 
skeletal growth factor.20 Overall, IGF-1 acts to promote bone 
formation and increases cancellous bone volume21 (Figure 2). 
IGF-1 is primarily produced by the liver, but also by bone 
cells. Parathyroid hormone plays an important role in IGF-1 
action, because parathyroid hormone increases the production 
of IGF-1 by bone cells. Subsequently, IGF-1 acts primarily 
on differentiated osteoblasts by increasing osteoblast function 
and subsequent new bone formation.21 IGF-1 also prevents 
apoptosis of differentiated osteoblasts, which also contributes 
to the anabolic effect of pulsatile parathyroid hormone, ie, 
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The Wnt-β-catenin pathway plays an important role in 
osteoblastogenesis.22,23 This pathway may also be upregulated 
with pulsatile parathyroid hormone because sclerostin, a Wnt-
β-catenin antagonist, is downregulated after activation of 
parathyroid hormone.24 Sclerostin is expressed by osteoblasts 
and osteocytes, and acts through binding to Wnt coreceptors, 
which in turn prevents Wnt signalling. This upregulation of 
Wnt-β-catenin may also contribute to the anabolic action of 
teriparatide.24
Beneficial effects of parathyroid 
hormone treatment
Conventional treatments for osteoporosis, including 
  bisphosphonates, selective estrogen receptor modulators, 
calcitonin, and estrogen, have been shown to reduce the rate 
of bone resorption and preserve bone mass.25 However, none 
of these have been shown to stimulate new bone   formation.25 
Teriparatide [recombinant hPTH-(1–34)] is an agent 
shown to increase both bone mass and bone strength.26 The 
  Fracture Prevention Trial compared the effect of teriparatide 
20 µg/day versus placebo in postmenopausal women.26 In 
this trial,   teriparatide was shown to increase lumbar spine 
and femoral neck BMD and decreased the incidence of both 
vertebral and nonvertebral fractures in postmenopausal 
women with osteoporosis.26 This trial showed a reduction 
in the number of new vertebral fractures (relative risk [RR] 
0.35) and in new nonvertebral fractures (RR 0.54).26 The 
fracture prevention benefits of teriparatide were also shown 
to be independent of age and initial BMD.27
Aside from its effect on BMD values, teriparatide also 
had a positive effect on non-BMD determinants of bone 
strength.28,29 Finally, teriparatide has also been shown to 
improve certain aspects of health-related quality of life. In 
particular, there are improvements in pain symptoms, certain 
↑ PPAR-γ2 ↑ RANK-L 
↑ Caspase 3 ↑ M-CSF 
↓ Wnt  ↓ OPG 
Decrease bone formation  Increase bone resorption
Glucocorticoid use
Osteoblasts Osteoclasts
Increase rate of apoptosis
Decrease rate of differentiation 
Decrease osteoblast function
Decrease rate of apoptosis
Increase rate of differentiation 
Increase osteoclast function
Figure 1 Downstream effect of glucocorticoids on bone metabolism.
Abbreviations: PPAR-γ2, peroxisome proliferator-activated receptor-γ2; RANK-L, receptor activation of nuclear factor κB ligand; M-CSF, macrophage colony-stimulating 
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aspects of emotional functioning, activities of daily living, 
and leisure activities also appear to improve with therapy.30
Use of teriparatide in GIOP
GIOP has a significant impact on morbidity and health-related 
quality of life in the patients that it affects. General preven-
tion strategies include eliminating the dosage of exogenous 
glucocorticoids, and supplementation with calcium and 
vitamin D. Certain patients will also require pharmacologic 
therapy to prevent further bone loss and reduce risk of future 
fractures.
Current guidelines for GIOP management recommend 
treatment with bisphosphonates, and in particular, treatment 
with alendronate or risedronate. In high-risk patients, the 
addition of a bisphosphonate is recommended early in the 
course of glucocorticoid therapy.31,32
After reviewing the pathophysiology of GIOP, and the 
mechanisms by which teriparatide exerts its anabolic effects 
on bone, it is understandable why teriparatide is thought to be 
a rational treatment option. Teriparatide directly stimulates 
osteoblastogenesis and inhibits osteoblast apoptosis, thus 
enhancing new bone formation with a subsequent increase in 
BMD. As mentioned earlier, glucocorticoids have deleterious 
effects on bone through promoting osteoblast apoptosis and 
inhibiting osteoblastogenesis, and thus teriparatide seems to 
be a physiologically rational treatment.
Parathyroid hormone was first used in the treatment of 
GIOP by Lane et al in 1998. They conducted a randomized 
controlled trial of teriparatide in postmenopausal women 
with osteoporosis who were also taking corticosteroids and 
hormone replacement. After treatment for 12 months, lumbar 
spine BMD increased by 11% as measured by dual-energy 
X-ray absorptiometry (DXA) and by 35% as measured by 
quantitative computed tomography (QCT).33 This compared 
with a 0% increase measured by DXA (P , 0.001) and a 
1.7% increase measured by QCT (P , 0.001) in the group 
treated with estrogen therapy only.33
Lane et al also followed this group of patients treated 
with teriparatide for an additional 12 months after the   initial 
  treatment duration of 12 months was completed. BMD 
of the lumbar spine were quantified using QCT.34 BMD 
measurements were also assessed at the lumbar spine, hip, 
and forearm using DXA. At 24-month follow-up, there was 
a 45.9% increase in BMD at the lumbar spine when assessed 
by QCT (P , 0.001) and a 12.6% increase when assessed 
by DXA (P , 0.001). The change in total hip and femoral 
neck BMD were not significant compared with the estrogen 
therapy alone group at 12 months, but there was a 4.7% 
increase (P , 0.01) for the total hip, and a 5.2% increase 
(P , 0.01) at the femoral neck at 24 months. The mean 
percent differences in BMD of the lumbar spine by QCT 
and DXA between the groups at 24 months were 43.1% 
and 11.9%, respectively, favoring the teriparatide group 
(P , 0.001). These results suggest that parathyroid hormone 
treatment in conjunction with estrogen therapy results in a 
significant BMD increase in the lumbar spine and hip in 
postmenopausal women with GIOP when compared with 
treatment with estrogen alone.34 However, what is more 
interesting is that bone mass continued to increase after 
parathyroid hormone treatment (of 12 months’ duration) was 
discontinued, and this is particularly true for BMD values at 
the total hip and femoral neck.34
Furthermore, treatment with teriparatide in postmenopausal 
women with GIOP was shown to increase not only BMD, 
but also to increase vertebral cross-section area, which 
was obtained by QCT of the L1 and L2 vertebrae.35 After 
a 12-month course of teriparatide treatment, the vertebral 
cross-section area increased by 4.8% (P , 0.001 compared 
with baseline), and on the follow-up assessment at 24 months 
(12 months after therapy was discontinued), the vertebral 
cross-section area was still 2.6% higher than the baseline 
value (P , 0.05). No change in vertebral cross-section area 
was seen in the control group.35
↑ Differentiation                PTH
             ↑ Function GH
Preosteoblasts
Osteoblasts ↑
↑
Increase bone
formation 
IGF-1
Figure 2 Role of pulsatile parathyroid hormone on osteoblast differentiation and 
function.
Abbreviations: PTH, parathyroid hormone; iGF-1, insulin-like growth factor-1; 
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To assess the efficacy of teriparatide compared with 
that of alendronate in patients with GIOP further, Saag et al 
conducted a double-blind, controlled trial comparing the 
two treatments.36 The study included both men and women 
(aged 22–89 years, mean 57.3 years in the   alendronate 
group, mean 56.1 years in the teriparatide group) who had 
received   glucocorticoids for at least three months (  prednisone 
equivalent $5 mg daily). A total of 214 patients were 
  randomized to receive teriparatide 20 µg daily, and 214 
patients were randomized to receive alendronate 10 mg daily. 
The primary outcome was change in BMD at the lumbar 
spine, and secondary outcomes included changes in BMD 
at the total hip, time to change in BMD, incidence of new 
fractures, and also measures of bone turnover markers. After 
36 months of follow-up, there was a significantly greater 
increase in BMD of the lumbar spine in the teriparatide group, 
with an 11.0% increase in the teriparatide group, compared 
with a 5.3% increase in the alendronate group (P , 0.001). 
There was also a greater increase in BMD at the total hip 
(5.2% in the teriparatide group versus 2.7% in the alendronate 
group, P , 0.001) and femoral neck (6.3% in the teriparatide 
group versus 3.4% in the alendronate group, P , 0.001).36
Regarding its ability to reduce fractures, three of 173 
patients in the teriparatide group were found to have a new 
vertebral radiographic fracture (1.7%). This compared 
with 13 of 169 patients (7.7%) with vertebral radiographic 
fractures in the alendronate group.36 This was statistically 
significant between the two groups, with a P value of 0.007. 
There was also a statistically significant difference in clini-
cal vertebral fractures, with four of 160 patients (2.4%) in 
the alendronate group, compared with 0 of 173 patients in 
the teriparatide group, with a P value of 0.037. There was 
no statistically significant difference between the groups 
regarding incidence rates of nonvertebral fractures (7.0% 
in alendronate group versus 7.5% in the teriparatide group, 
P = 0.843) or rates of nonvertebral fragility fractures (2.3% in 
the alendronate group versus 4.2% in the teriparatide group, 
P = 0.256). Also of interest is that the duration of teriparatide 
treatment in this trial was 36 months, which is longer than 
the usual duration of 24 months.
Post hoc analysis was performed to assess the effect of 
baseline glucocorticoid dose on BMD values at the lumbar 
spine, femoral neck, and total hip in patients treated with 
teriparatide or alendronate.37 For the analysis, patients were 
divided into a low-dose glucocorticoid group (#5 mg pred-
nisone/day), a medium-dose group (5–15 mg/day), and a 
high-dose group (.15 mg per day). In patients treated with 
teriparatide, lumbar spine BMD increased by 8.1% in the low-
dose group, 6.6% in the medium-dose group, and 4.6% in the 
high-dose group. This is compared with patients treated with 
alendronate, whereby the lumbar spine BMD increased by 
3.6% in the low-dose group, 2.8% in the medium-dose group, 
and 2.3% in the high-dose group.37 There was no significant 
difference in BMD at the femoral neck and total hip in either 
treatment group for the various glucocorticoid doses.
Teriparatide has also been shown to have effects on 
bone formation markers in patients with GIOP.38 In a 
study including 159 females and 38 males with GIOP, 
serum osteocalcin and procollagen type I N-terminal 
propeptide (PINP) were measured in patients randomized 
to   alendronate or teriparatide. At baseline, bone forma-
tion markers were below the reference interval in 33% of 
patients for osteocalcin and 4% of patients for PINP. After 
six months of therapy, patients in the teriparatide group 
had a median increase in osteocalcin levels by 92% and 
in PINP levels by 108%. In the same time interval, the 
alendronate group had a decrease in median osteocalcin 
levels by 40% and a decrease in PINP level by 53%.38 It 
is unclear which bone turnover marker is best to measure 
in patients with GIOP treated with teriparatide. Serum 
levels of PINP, procollagen type I C-terminal peptide, and 
bone alkaline phosphatase show significant rises after one 
month of treatment with teriparatide. The changes in PINP 
levels at one and six months after teriparatide treatment did 
correlate with changes in femoral neck and lumbar spine 
BMD at 18 months post-treatment. The other parameters 
did not correlate with BMD changes after 18 months of 
teriparatide treatment.
There are a number of side effects which are seen more 
frequently in the teriparatide group compared with those 
taking placebo. They have higher frequencies of developing 
nausea (RR = 2.34), abdominal cramps (RR = 3.22), and 
hypercalcemia (RR = 9.73).26 In the Fracture Prevention 
Trial, hypercalcemia (.10.6 mg/dL) was seen in 11% of 
patients in the teriparatide group, and 3% of patients had 
successive measurements in the hypercalcemia range,26 
although this was not sustained. Currently there are no 
recommendations regarding monitoring of serum calcium 
in patients taking teriparatide. Calcium and vitamin D 
intake through dietary and supplementary sources should 
be carefully considered based on serum calcium levels. If 
hypercalcemia persists on teriparatide therapy, then it should 
be discontinued, and serum calcium levels should be reas-
sessed in 7–10 days.39Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Recently, there has been great interest in the association 
between atypical fractures of the femur and bisphosphonate 
therapy. There are a number of clinical risk factors which 
increase the risk of developing an atypical femoral fracture. 
Glucocorticoid use may be an important risk factor in this 
process, although the exact mechanism involved is unknown. 
In a recent systematic review of case reports and case series, 
nearly 40% of Caucasian women with atypical femur frac-
tures were using glucocorticoids.40 Teriparatide therapy 
should theoretically be free of this risk due to a completely 
different mechanism of action. Thus, teriparatide may be 
a useful option in GIOP patients who develop an atypical 
fracture of the femur.
Conclusion
In conclusion, GIOP is a common and potentially debilitating 
consequence of glucocorticoid therapy. Teriparatide has been 
shown to be efficacious in patients with postmenopausal 
osteoporosis. This review of the current clinical evidence 
suggests that teriparatide may be an efficacious and promising 
agent in the treatment of GIOP.
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